Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death

Journal of Neuro-Oncology

Volumn 86, Issue 1, 2008, Pages 23-30

  Tallen, Ute Gesche ^a   Truss, Matthias ^a   Kunitz, Frank ^a   Wellmann, Sven ^b   Unryn, Brad ^c   Sinn, Brigitte ^a   Lass, Ulrike ^d   Krabbe, Sonja ^a   Holtkamp, Nikola ^a   Hagemeier, Christian ^a   Wurm, Reinhard ^a   Henze, Guenter ^a   Riabowol, Karl T ^c   von Deimling, Andreas ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cisplatin; DNA damage; Glioblastoma multiforme; ING1 isoforms

Indexed keywords

CISPLATIN; DNA; HISTONE; INHIBITOR OF GROWTH 1 PROTEIN; PROTEIN P47; PROTEIN P53; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; DEACETYLATION; DISEASE COURSE; DNA DAMAGE; DOWN REGULATION; DRUG SENSITIZATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IONIZING RADIATION; PHASE TRANSITION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DOWN-REGULATION; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NUCLEAR PROTEINS; RADIATION; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 37249077458     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9436-x     Document Type: Article

References (42)

1. Garkavtsev I, Demetrick D, Riabowol K (1997) Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1). Cytogenet. Cell Genet 76:176-78
2. Feng X, Hara Y, Riabowol K (2002) Different HATS of the ING1 gene family. Trends Cell Biol 12(11):532-538
3. Takahashi M, Ozaki T, Todo S et al (2004) Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas. Oncol Rep 12(4):811-816
4. Russell M, Berardi P, Gong W et al (2006) Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 312(7):951-961
5. Scott M, Bonnefin P, Vieyra D et al (2001) UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. J Cell Sci 114(Pt 19):3455-3462
6. Martin DGE, Baetz K, Shi X et al (2006) The Yng1p PHD finger is a methyl-histone binding module that recognizes lysine 4 methylated histone H3. Mol Cell Biol 26(21):7871-7879
7. Pena PV, Davrazou F, Shi X et al (2006) Molecular mechanism of H3K4me3 recognition by plant homeodomain of ING2. Nature 442:100-103
8. Shi X, Hong T, Walter KL et al (2006) ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442:96-99
9. Li H, Ilin S, Wang W et al (2006) Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 442:91-95
10. Vieyra D, Loewith R, Scott M et al (2002) Human ING1 proteins differentially regulate histone acetylation. J Biol Chem 277(33):29832-29839
11. Garkavtsev I, Kazarov A, Gudkov A et al (1996) Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet 14:415-420
12. Kadigee MR, Ayer DE (2006) The polybasic region that follows the plant homeodomain zinc finger 1 of PF1 is necessary and sufficient for specific phosphoinositide binding. J Biol Chem 281(39):28831-28836
13. Shinoura N, Muramatsu Y, Nishimura M et al (1999) Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res 59(21):5521-5528
14. Helbing CC, Veillette C, Riabowol K et al (1997) A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res 57(7):1255-1258
15. Zhu JJ, Li FB, Zhou JM, Liu ZC et al (2005) The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells. Cancer Biol Ther 4(1):39-47
16. Vieyra D, Toyama T, Hara Y et al (2002) ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res 62(15):4445-4452
17. Garkavtsev I, Grigorian IA, Ossovskaya VS et al (1998) The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391(6664):295-298
18. Coles AH, Liang H, Zhu Z et al (2007) Deletion of p37Ing1 in mice reveals a p53-independent role for Ing1 in the suppression of cell proliferation, apoptosis, and tumorigenesis. Cancer Res 67(5):2054-2061
19. Feng X, Bonni S, Riabowol K (2006) HSP70 induction by ING1 proteins sensitizes cells to TNF-α receptor mediated apoptosis. Mol Cell Biol 26(24):9244-9255
20. Cheung KJ Jr, Li G (2002) p33(ING1) enhances UVB-induced apoptosis in melanoma cells. Exp Cell Res 279(2):291-298
21. Scott M, Boisvert FM, Vieyra D et al (2001) UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. Nucleic Acids Res 29(10):2052-2058
22. Cheung KJ Jr, Mitchell D, Lin P et al (2001) The tumor suppressor candidate p33(ING1) mediates repair of UV-damaged DNA. Cancer Res 61(13):4974-4977
23. Tallen G, Riabowol K, Wolff JE (2003) Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. Anticancer Res 23(2B):163-165
24. Gong W, Suzuki K, Russell M et al (2005) Function of the ING family of PHD proteins in cancer. Int J Biochem Cell Biol 37(5):1054-1065
25. Vieyra D, Senger DL, Toyama T et al (2003) Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. Clin Cancer Res 9(16 Pt 1):5952-5961
26. Tallen G, Kaiser I, Krabbe S et al (2004) No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. Int J Cancer 109(3):476-479
27. Bernstein C, Bernstein H, Payne CM et al (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat Res 511(2):145-178
28. Tallen G, Mock C, Gangopadhyay SB et al (2000) Overcoming cisplatin resistance: Design of novel hydrophobic platinum compounds. Anticancer Res 20(1A):445-449
29. Wellmann S, Taube T, Paal K et al (2001) Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin Chem 47(4):654-660
30. Boland D, Olineck V, Bonnefin P et al (2000) A panel of CAb antibodies recognize endogenous and ectopically expressed ING1 protein. Hybridoma 19(2):161-165
31. Medina D, Moskowitz N, Khan S et al (2000) Rapid purification of protein complexes from mammalian cells. Nucleic Acids Res 28(12):E61
32. Gilligan D, Mort C, McMillan TJ et al (1996) Application of a bromodeoxyuridine-Hoechst/ethidium bromide technique for the analysis of radiation-induced cell cycle delays in asynchronous populations. Int J Radiat Biol 69(2):251-257
33. Ishii N, Maier D, Merlo A et al (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479
34. Xu GW, Mymryk JS, Cairncross JG (2005) Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. J Neurooncol 74(2):141-149
35. Park CM, Park MJ, Kwak HJ et al (2006) Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int J Oncol 28(1):119-125
36. Fruehauf JP, Brem H, Brem S et al (2006) In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12(15):4523-4532
37. Schlapbach R, Fontana A (1997) Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. Biochim Biophys Acta 1359:174-180
38. Shen D-H, Chan KY-K, Khoo U-S et al (2005) Epigenetic and genetic alterations of p33 ING1b in ovarian cancer. Carcinogenesis 26(4):855-863
39. Kuzmichev A, Zhang Y, Erdjument-Bromage H et al (2002) Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Mol Cell Biol 22(3):835-848
40. Doyon Y, Cayrou C, Ullah M et al (2006) ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 21(1):51-64
41. Liu T, Kuljaca S, Tee A et al (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32(3):157-165
42. Minucci S, Pelicci P (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38-51